Data regarding risk factors and long-term outcomes of U.S. patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease (MASLD) are limited.
Advanced fibrosis linked to liver complications in biopsy-proven MASLD
- Post author:
- Post published:October 25, 2024
- Post category:uncategorized